| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $346,983,858 ) (Continued on the next page) |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | U2RTW010114 | 2/2 ? Regional GEOHealth Hub Centered in Peru-U.S. | 001 | 6 | NIH | 6/3/2022 | $299,989 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI125064 | Antiviral role of CD8+T cells in ART-treated SIV-infected macaques | 001 | 7 | NIH | 3/16/2022 | $909,998 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | U24AI120134 | Development of multi-modal single-cell technology to dissect epitope specificity to HIV | 001 | 8 | NIH | 6/1/2022 | $660,361 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI120860 | Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles | 000 | 8 | NIH | 5/11/2022 | $538,140 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01HD082373 | NMDAR Mutations & Neurodevelopmental Disorder: from Mechanism to Targeted Therapy | 002 | 7 | NIH | 5/11/2022 | $331,966 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | D43TW010934 | Emory-Nigeria HIV Research Training Program (EN-RTP) | 000 | 4 | NIH | 3/15/2022 | $300,599 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | P30AI050409 | Center for AIDS Research at Emory University | 000 | 24 | NIH | 5/12/2022 | $267,000 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | P30AI050409 | Center for AIDS Research at Emory University | 000 | 24 | NIH | 5/12/2022 | $200,000 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | P30AI050409 | Center for AIDS Research at Emory University | 000 | 24 | NIH | 5/12/2022 | $85,500 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | 003 | 13 | NIH | 5/10/2022 | $2,582,250 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | P30CA138292 | Winship Cancer Institute Cancer Center Support Grant | 004 | 13 | NIH | 5/17/2022 | $60,000 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | K12HD072245 | Atlanta Pediatric Scholars Program | 000 | 10 | NIH | 12/1/2021 | $449,255 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01DK080684 | Mechanism of Enteric Neuropathy | 000 | 12 | NIH | 3/29/2022 | $434,686 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01NS065992 | The role of intrinsic cellular excitability in homeostatic plasticity of developing circuits | 001 | 11 | NIH | 3/23/2022 | $36,212 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01NS065992 | The role of intrinsic cellular excitability in homeostatic plasticity of developing circuits | 000 | 11 | NIH | 3/16/2022 | $325,910 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI088025 | RNA modification and antibiotic resistance | 000 | 13 | NIH | 4/14/2022 | $538,260 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01GM093278 | Molecular Basis of Ribosomal Frameshifting | 000 | 12 | NIH | 6/21/2022 | $105,749 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01NS091201 | Urokinase-type Plasminogen Activator in the Ischemic Brain | 000 | 7 | NIH | 11/15/2021 | $401,625 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01NS091201 | Urokinase-type Plasminogen Activator in the Ischemic Brain | 001 | 7 | NIH | 3/24/2022 | $44,625 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01NS091201 | Urokinase-type Plasminogen Activator in the Ischemic Brain | 002 | 7 | NIH | 6/17/2022 | $455,000 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | K12HD085850 | Emory University BIRCWH Program | 000 | 8 | NIH | 6/13/2022 | $250,000 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | K12HD085850 | Emory University BIRCWH Program | 000 | 8 | NIH | 6/13/2022 | $154,186 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | T32NR012715 | Training in Interventions to Improve Outcomes in Chronic Conditions | 000 | 10 | NIH | 6/15/2022 | $450,383 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI030048 | T cell Memory to Viruses | 000 | 29 | NIH | 2/10/2022 | $561,600 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | UM1AI069418 | Emory-CDC CTU | 000 | 16 | NIH | 11/23/2021 | $1,325,529 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | UM1AI069418 | Emory-CDC CTU | 000 | 16 | NIH | 11/23/2021 | $605,705 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | UM1AI069418 | Emory-CDC CTU | 002 | 16 | NIH | 6/15/2022 | $847,469 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI072435 | Characterization of Lamprey B cells and Antibodies | 000 | 16 | NIH | 4/11/2022 | $444,712 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI116933 | Genetic Mechanisms of Sporulation Induction in C. difficile | 000 | 7 | NIH | 1/12/2022 | $478,027 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | K24AI114444 | Mentorship in Patient-Oriented Research in Tuberculosis, HIV and Global Health | 000 | 9 | NIH | 5/20/2022 | $184,334 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | U19AI110483 | Molecular Regulation of B cells and T cells in Human SLE | 003 | 9 | NIH | 5/23/2022 | $88,782 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | U19AI110483 | Molecular Regulation of B cells and T cells in Human SLE | 002 | 9 | NIH | 5/19/2022 | $46,256 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R25MH101079 | Emory Psychiatry Clinical Scientist Training Program (CSTP) | 000 | 7 | NIH | 4/6/2022 | $210,192 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | U19AI110483 | Molecular Regulation of B cells and T cells in Human SLE | 000 | 9 | NIH | 5/11/2022 | $4,808,545 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI113021 | Regulation of Human PD-1 Gene Expression | 000 | 8 | NIH | 5/16/2022 | $462,039 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01AI113021 | Regulation of Human PD-1 Gene Expression | 000 | 8 | NIH | 5/16/2022 | $82,220 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R37AI112787 | Targeting PD-1 Pathway for Functional Cure of AIDS | 000 | 9 | NIH | 1/19/2022 | $826,489 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31CA243472 | Delineating the role of calcineurin in modulating the immune response in acute lymphoblastic leukemia | 001 | 3 | NIH | 6/7/2022 | $716 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31CA243472 | Delineating the role of calcineurin in modulating the immune response in acute lymphoblastic leukemia | 000 | 3 | NIH | 3/1/2022 | $46,036 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | T32AI106699 | Antimicrobial Resistance and Therapeutic Discovery Training Program | 001 | 8 | NIH | 5/24/2022 | $3,867 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | T32AI106699 | Antimicrobial Resistance and Therapeutic Discovery Training Program | 000 | 8 | NIH | 3/31/2022 | $260,094 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R25DK101390 | Summer Undergraduate Program in Emory Renal Research (SUPERR) | 000 | 9 | NIH | 4/14/2022 | $113,967 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31AI161911 | The role of TIGIT in Treg-mediated suppression of C8+ T cells in Transplantation | 001 | 1 | NIH | 5/27/2022 | $716 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31AI161911 | The role of TIGIT in Treg-mediated suppression of C8+ T cells in Transplantation | 000 | 1 | NIH | 3/3/2022 | $46,036 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01CA175316 | Transcription-dependent and -independent signaling of RSK2 in cancer metastasis | 001 | 9 | NIH | 4/26/2022 | $29,640 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01CA175316 | Transcription-dependent and -independent signaling of RSK2 in cancer metastasis | 000 | 9 | NIH | 3/7/2022 | $333,450 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | R01HL130995 | Germline mutations of PTPN11 (SHP2) in the stem cell microenvironment | 001 | 6 | NIH | 6/10/2022 | $462,947 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31CA243502 | DNA mechanotechnology to investigate the role of PD1 biophysics in T cell signaling | 001 | 3 | NIH | 5/27/2022 | $716 |
| | 2022 | 2022 | EMORY UNIVERSITY | 201 DOWMAN DR | ATLANTA | GA | 30322-1007 | DEKALB | USA | F31CA243502 | DNA mechanotechnology to investigate the role of PD1 biophysics in T cell signaling | 000 | 3 | NIH | 11/8/2021 | $46,036 |
|
